PMID- 25206908
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140910
LR  - 20240321
IS  - 1673-5374 (Print)
IS  - 1876-7958 (Electronic)
IS  - 1673-5374 (Linking)
VI  - 9
IP  - 9
DP  - 2014 May 1
TI  - Stem cells in neuroinjury and neurodegenerative disorders: challenges and future 
      neurotherapeutic prospects.
PG  - 901-6
LID - 10.4103/1673-5374.133129 [doi]
AB  - The prevalence of neurodegenerative diseases and neural injury disorders is 
      increasing worldwide. Research is now focusing on improving current neurogenesis 
      techniques including neural stem cell therapy and other biochemical drug-based 
      approaches to ameliorate these disorders. Unfortunately, we are still facing many 
      obstacles that are rendering current neurotherapies ineffective in clinical 
      trials for reasons that are yet to be discovered. That is why we should start by 
      fully understanding the complex mechanisms of neurogenesis and the factors that 
      affect it, or else, all our suggested therapies would fail since they would not 
      be targeting the essence of the neurological disorder but rather the symptoms. 
      One possible paradigm shift is to switch from neuroprotectant therapies towards 
      neurodegeneration/neurorestorative approaches. In addition, other and our 
      laboratories are increasingly focusing on combining the use of pharmacological 
      agents (such as Rho-associated kinase (ROCK) inhibitors or other growth factors 
      (such as brain-derived neurotrophic factor (BDNF)) and stem cell treatment to 
      enhance the survivability and/or differentiation capacity of transplanted stem 
      cells in neurotrauma or other neurodegeneration animal models. Ongoing stem cell 
      research is surely on the verge of a breakthrough of multiple effective 
      therapeutic options for neurodegenerative disorders. Once, we fully comprehend 
      the process of neurogenesis and its components, we will fully be capable of 
      manipulating and utilizing it. In this work, we discuss the current knowledge of 
      neuroregenerative therapies and their associated challenges.
FAU - Mouhieddine, Tarek H
AU  - Mouhieddine TH
AD  - Faculty of Medicine, American University of Beirut Medical Center, Beirut, 
      Lebanon.
FAU - Kobeissy, Firas H
AU  - Kobeissy FH
AD  - Faculty of Medicine, American University of Beirut Medical Center, Beirut, 
      Lebanon ; Center for Neuroproteomics and Biomarkers Research, Department of 
      Psychiatry, Gainesville, Division of Addiction Medicine, Department of 
      Psychiatry, University of Florida, Gainesville, FL 32610, USA.
FAU - Itani, Muhieddine
AU  - Itani M
AD  - Faculty of Medicine, Saint George University of London, Nicosia, Cyprus.
FAU - Nokkari, Amaly
AU  - Nokkari A
AD  - Department of Biochemistry and Molecular Genetics, American University of Beirut, 
      Beirut, Lebanon.
FAU - Wang, Kevin K W
AU  - Wang KK
AD  - Center for Neuroproteomics and Biomarkers Research, Department of Psychiatry, 
      Gainesville, Division of Addiction Medicine, Department of Psychiatry, University 
      of Florida, Gainesville, FL 32610, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Neural Regen Res
JT  - Neural regeneration research
JID - 101316351
PMC - PMC4146225
OTO - NOTNLM
OT  - BDNF
OT  - TBI
OT  - growth factors
OT  - neural stem cells
OT  - neurodegeneration
OT  - neuroinjury
OT  - rho-associated kinase (ROCK) inhibitor
OT  - stem cell therapy
COIS- Conflicts of interest: None declared.
EDAT- 2014/09/11 06:00
MHDA- 2014/09/11 06:01
PMCR- 2014/05/01
CRDT- 2014/09/11 06:00
PHST- 2014/04/15 00:00 [accepted]
PHST- 2014/09/11 06:00 [entrez]
PHST- 2014/09/11 06:00 [pubmed]
PHST- 2014/09/11 06:01 [medline]
PHST- 2014/05/01 00:00 [pmc-release]
AID - NRR-9-901 [pii]
AID - 10.4103/1673-5374.133129 [doi]
PST - ppublish
SO  - Neural Regen Res. 2014 May 1;9(9):901-6. doi: 10.4103/1673-5374.133129.